




ARCHIVOS DE Bronconeumología

www.archbronconeumol.org



Scientific Letter

Real Life Experience in Short Treatments for Community-Acquired Pneumonia: An Observational Propensity Cohort Study

To the Director,

Community-acquired pneumonia (CAP) continues to represent a significant burden on global public health, with substantial morbidity and mortality.^{1,2} Despite advancements in diagnostics and therapeutics, uncertainties persist regarding the optimal duration of antibiotic therapy, particularly for hospitalized patients.

Antibiotic stewardship is a cornerstone in the management of infectious diseases, aiming to optimize patient outcomes by improving adherence and minimizing the risks associated with antibiotic overuse, such as the emergence of antimicrobial resistance and adverse drug reactions.³ In recent years, clinical trials and meta-analyses have suggested that shorter courses of antibiotics may be as effective as longer durations in achieving clinical cure for patients with CAP.^{4–6} These findings have been reflected in guideline recommendations.⁷

Despite this, physicians struggle with reducing treatment durations, as shown in some studies in which up to 70–93% of patients are prescribed excessive treatment durations.^{8,9} Evidence to evaluate short regimens in a real-life setting could enhance practitioner's confidence in short treatments, which is why we designed this study.

The objectives were to compare 30-day mortality and 30-day readmissions between patients receiving a short-course treatment (7 days) and patients receiving longer courses (8–10 days) for CAP that require hospitalization.

We conducted a retrospective cohort study. Briefly, we included consecutive adult patients hospitalized during two one-year periods: 2007–2008 and 2017–2018. These patients belonged to the cohort of a previously published study.¹⁰ Basal characteristics, etiology and outcomes remained consistent between the two periods. Subjects with aspiration or nosocomial pneumonia were excluded. Those who received treatment for less than 7 days were also excluded to prevent selection bias, as their treatment duration was mostly not influenced by physician's decision, often resulting from transfers to other facilities or death. Participants presenting complicated CAP (empyema, necrotizing pneumonia, or abscess) were not included as they should receive longer treatment regimens. Patients were categorized based on treatment duration: 7-day (short-course) or 8–10-day (long-course).

We performed an unvaried and a multivariate analysis (with Lasso methodology for variable selection) by binary logistic regression to identify variables independently associated with mortality and readmission. Non-redundant variables with a p value ≤ 0.05 on the unvaried analysis, or those considered clinically relevant, were included in the multivariate analysis. A propensity score analysis

by Inverse Probability of Treatment Weighting (IPTW) was used to match both groups and to assess an adjusted mortality and readmission analysis. Variables included in the propensity-score model were septic shock, PSI mortality class, age, radiological pattern (bilateral vs unilateral consolidation), respiratory failure, ICU admission, any comorbidity, CURB-65, bacteremia, bacterial etiology, *Staphylococcus aureus* etiology, any immunosuppressive condition, nursing home, flu-season (November–March, both included), flu-vaccine, smoking, *Streptococcus pneumoniae* vaccine, sex and alcohol consumption. Statistical analyses were performed using the IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY; IBM Corp. Released 2011 and Stata 15.1.

Overall, 602 patients were enrolled, 277 in the short-course group and 325 in the prolonged-course group. The mean age was 63.6 years (standard deviation 19.1) and 220 (36.4%) were women. **Table 1** shows baseline characteristics and clinical parameters of patients receiving short vs long treatment courses. There were no differences in terms of sex, underlying conditions and immunosuppressive factors between both groups, but patients receiving longer treatments were slightly older (60.6 vs 66.2 years, $p < 0.001$). In terms of severity, patients with bilateral involvement ($p = 0.029$), septic shock ($p < 0.001$), respiratory failure ($p = 0.037$) or those who presented higher PSI scores ($p < 0.001$) received more frequently long antibiotic courses.

Regarding outcomes, there were no significant disparities in 30-day mortality ($p = 0.189$) or 30-day readmissions ($p = 0.86$) between the short-course and prolonged-course groups. Multivariate analyses revealed that ICU admission was the sole factor associated with 30-day mortality. There was no association between short-course antibiotic treatment and mortality (**Table 2**). Furthermore, age emerged as the only variable associated with 30-day readmission.

A propensity score model was performed to adjust the basal characteristics of both groups and it also failed to uncover significant differences in 30-day mortality (OR:2.23; 95%CI, 0.35–10.9, $p = 0.325$) or readmission (OR:0.89; 95%CI, 0.38–2.09, $p = 0.79$) between patients receiving 7-day versus 8–10-day treatments.

Our study examines a large cohort of adult patients with severe pneumonia, applying a propensity-score model. Results indicate that two robust endpoints, such as 30-day mortality and 30-day readmissions are similar in subjects treated for 7 days and those treated 8–10 days. It is noteworthy that, among the patients who received a short treatment-course, 40% presented a PSI score class IV or V and even 4.7% of them were admitted in the ICU.

Different clinical trials have addressed the issue of treatment duration in adult patients with CAP. Trials comparing 5 or 3 days with longer courses yielded similar clinical success rates but enrolled predominantly low risk patients.^{5,11} A Spanish study that randomized patients to stop or continue with antibiotics after 5 days presented similar results, however most of the patients

<https://doi.org/10.1016/j.arbres.2024.04.018>

0300-2896/© 2024 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Please cite this article as: J. Sellarès-Nadal, J. Burgos, M.T. Martín-Gómez et al., Real Life Experience in Short Treatments for Community-Acquired Pneumonia: An Observational Propensity Cohort Study, Archivos de Bronconeumología, <https://doi.org/10.1016/j.arbres.2024.04.018>

Table 1
Baseline characteristics, outcomes and other relevant factors of patients that received short and long antibiotic courses.

Characteristics	7 days n = 277 (%)	8–10 days n = 325 (%)	p
<i>Basal characteristics</i>			
Age, years	60.6 (19.2)	66.15 (18.7)	<0.001
Female	98 (35.4)	121 (37.2)	0.638
Smoking (>5 cig/day)	66 (23.8)	74 (22.8)	0.760
Alcohol (>60 g/day)	21 (7.6)	20 (6.2)	0.488
Nursing home	14 (5.1)	17 (5.2)	0.922
<i>Underlying conditions</i>			
Any underlying condition ^a	148 (53.4)	193 (59.4)	0.142
Any immunosuppressive condition ^b	51 (18.4)	61 (18.8)	0.911
<i>Previous vaccination</i>			
Pneumococcal vaccination (previous 5 years)	31 (11.2)	33 (10.2)	0.681
Influenza vaccination	82 (29.6)	93 (28.6)	0.79
<i>Microbiology</i>			
<i>S. pneumoniae</i>	100 (35.8)	117 (36)	0.968
<i>S. aureus</i>	3 (1.1)	4 (1.2)	1.000
Legionella	9 (3.2)	13 (4.0)	0.613
Identification of any bacterial pathogen	144 (51.6)	172 (52.9)	0.748
Bacteraemic CAP	22 (7.9)	29 (8.9)	0.667
<i>Empirical treatment</i>			
Amoxicillin–clavulanate	147 (53.1)	163 (50.2)	0.513
3rd generation cephalosporin	72 (26)	98 (30.2)	0.276
Levofloxacin	38 (13.7)	32 (9.8)	0.161
Piperacillin–tazobactam	14 (5.1)	14 (4.3)	0.701
Other	6 (2.2)	18 (5.5)	0.04
<i>Severity scores</i>			
PSI high mortality classes (IV or V)	116 (41.9)	183 (56.3)	<0.001
CURB-65 ≥ 3	48 (17.3)	65 (20.0)	0.403
<i>Severity</i>			
Bilateral consolidation	18 (6.5)	38 (11.7)	0.029
ICU admission	13 (4.7)	28 (8.6)	0.057
Septic shock ^c	6 (2.2)	29 (8.9)	<0.001
Respiratory failure ^d	92 (33.2)	134 (41.2)	0.043
Invasive mechanical ventilation	4 (1.4)	13 (4.0)	0.082
<i>Treatment and hospitalization durations</i>			
Median (IQR) hospitalization length in days	4 (1–7)	6 (4–10)	<0.001
Median (IQR) treatment duration in days	7	10 (9–10)	
<i>Outcomes</i>			
30-Day mortality	2 (0.7)	7 (2.2)	0.189
30-Day readmission	11 (3.9)	12 (3.7)	0.859

^a Any underlying condition: chronic heart diseases, chronic lung disease, chronic renal disease, chronic neurological disease, cirrhosis, any malignancy with active treatment or HIV with CD4 count <200.

^b Any immunosuppressive factor: HIV infection, solid organ transplant, hematologic malignancies, solid organ neoplasm receiving active treatment, current treatment with biological therapies or other immunosuppressive agents.

^c Septic shock: need of vasoactive drugs.

^d Respiratory failure: pO₂ in arterial blood lower or equal to 60 mmHg or peripheral pulse oximetry lower than 90%.

Table 2
Unadjusted univariate and multivariate analysis of potential risk factors associated with 30-day mortality and 30-day readmission.

	Univariate analysis			Multivariate analysis		
	Odds ratio	95% CI	P value	Odds ratio	95% CI	P value
<i>30-Day mortality</i>						
Mean age in years	1.05	1–1.10	0.0525			
Bilateral consolidation	5.14	1.2–21.0	0.042			
ICU admission	19.4	5.0–75.4	<0.001	19.3	4.98–75.2	<0.001
Respiratory failure	3.41	0.84–13.7	0.086			
Septic shock	8.8	2.1–36.8	0.012			
Short course 7 days	3.05	0.63–14.7	0.188			
<i>30-Day readmission</i>						
Mean age in years	1.04	1.01–1.07	0.006	6.63	1.01–1.07	0.01
Any underlying condition	3.82	1.28–11.4	0.001			
Pneumococcal vaccination	3.2	1.2–8.4	0.014			
Influenza vaccination	2.79	1.2–6.46	0.012			
Short course 7 days	0.93	0.3–2.15	0.873			

received quinolone-based treatments, and the findings should not be extrapolated to β -lactam-based regimens.⁶ Dinh et al. published a clinical trial in which a 3-day course with β -lactams was compared to longer treatments and found non-inferiority of short treatments. Interestingly, this study included a high proportion of subjects with PSI score classes IV or V, however more than 75% did not present any comorbid condition.⁴

Although clinical trials offer the highest degree of scientific evidence, they can present problems of external validity since they usually have restrictive selection criteria.¹² Several meta-analyses and literature reviews have as well addressed the issue and have found no differences between patients receiving long and short treatment courses.^{13–15} The main limitation of these analyses is that they include heterogeneous studies, with highly variable treatment regimens, different inclusion criteria and disparate populations.

Observational studies may be more representative of real clinical practice as they include patients that are often excluded in the previously mentioned studies. Despite this, scarce studies focus on real-life experience to investigate the optimal treatment duration in adult patients hospitalized with CAP.¹⁶ These studies are prone to biases, such as the confounding by severity bias, in which patients with severe conditions are more likely to receive intensive or longer treatments than other subjects.¹² To mitigate this, statistical methods, such as propensity-score models should be applied. The only adjusted study assessing the subject is a recently published Danish study that found that hospitalized patients with CAP and early clinical response presented similar outcomes when they received short versus long-course treatments.¹⁷

As an observational retrospective, single center design the present study has limitations. Even though the propensity score model potentially corrects biases, we cannot assure that all factors were adjusted. This is why, we consider that this study does not allow to assure that all patients with severe presentations can be safely treated with a 7-day course. Probably the best strategy to guide duration of therapy depends on the clinical situation of the patients once they have received at least 5–7 days of treatment. Our study contributes insights to the ongoing discourse surrounding the optimal duration of antibiotic therapy for CAP. By endorsing shorter treatment durations in a pragmatic approach, we hope to catalyze practice changes and improve the quality of care for CAP patients.

Conflict of interest

The authors declare no conflicts of interest direct or indirectly related to this work.

References

1. File TM, Ramirez JA. Community-acquired pneumonia; 2023. p. 632–41.
2. Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. *Clin Infect Dis*. 2017;65:1806–12.
3. Dinh A, Crémieux A, Guillemot D. Short treatment duration for community-acquired pneumonia. *Curr Opin Infect Dis*. 2023;36:140–5.

4. Dinh A, Ropers J, Duran C, Davido B, Deconinck, Matt M, et al. Discontinuing β -lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. *Lancet*. 2021;397:1195–203.
5. El Moussaoui R, De Borgie CAJM, Van Den Broek P, Hustinx WN, Bresser P, Van Den Berk GEL, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. *Br Med J*. 2006;332:1355–8.
6. Uranga A, Espana PP, Bilbao A, Quintana JM, Arriaga I, Intxausti M, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. *JAMA Intern Med*. 2016;176:1257–65.
7. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med*. 2019;200:e45–67.
8. Yi SH, Hatfield KM, Baggs J, Hicks LA, Srinivasan A, Reddy S, et al. Duration of antibiotic use among adults with uncomplicated community-acquired pneumonia requiring hospitalization in the United States. *Clin Infect Dis*. 2018;66:1333–41.
9. Madaras-Kelly KJ, Burk M, Caplinger C, Bohan JG, Neuhauser MM, Goetz MB, et al. Total duration of antimicrobial therapy in veterans hospitalized with uncomplicated pneumonia: results of a national medication utilization evaluation. *J Hosp Med*. 2016;11:832–9.
10. Sellarès-Nadal J, Burgos J, Martín-Gómez MT, Antón A, Sordé R, Romero-Herrero D, et al. Community-acquired pneumonia in hospitalised patients: changes in aetiology, clinical presentation, and severity outcomes in a 10-year period. *Ann Med*. 2022;54:3052–9.
11. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. *Clin Infect Dis*. 2003;37:752–60.
12. McDonald EG, Prosty C, Hanula R, Bortolussi-Courval É, Albuquerque AM, Tong SYC, et al. Observational versus randomized controlled trials to inform antibiotic treatment durations: a narrative review. *Clin Microbiol Infect*. 2022;29:165–70.
13. Furlan L, Erba L, Trombetta L, Sacco R, Colombo G, Casazza G, et al. Short- vs long-course antibiotic therapy for pneumonia: a comparison of systematic reviews and guidelines for the SIMI Choosing Wisely Campaign. *Intern Emerg Med*. 2019;14:377–94.
14. Tansarli GS, Mylonakis E. Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults. *Antimicrob Agents Chemother*. 2018;62:1–13.
15. Viasus D, Vecino-Moreno M, De La Hoz JM, Carratalà J. Antibiotic stewardship in community-acquired pneumonia. *Expert Rev Anti Infect Ther*. 2017;15:351–9.
16. Parshall DM, Sessa JE, Conn KM, Avery LM. The impact of the duration of antibiotic therapy in patients with community-onset pneumonia on readmission rates: a retrospective cohort study. *J Pharm Pract*. 2021;34:523–8.
17. Israelsen SB, Fally M, Tarp B, Kolte L, Ravn P, Benfield T. Short-course antibiotic therapy for hospitalized patients with early clinical response in community-acquired pneumonia: a multicentre cohort study. *Clin Microbiol Infect*. 2022;29:54–60.

Júlia Sellarès-Nadal^{a,b,c}, Joaquín Burgos^{a,b,c,*},
María Teresa Martín-Gómez^d, Daniel Romero-Herrero^d,
Adrián Sánchez-Montalvá^{b,c}, Vicenç Falcó^{a,b,c}

^a Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain

^b Infectious Diseases Department, Vall d'Hebron, Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Barcelona, Spain

^c Malalties Infeccioses Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Barcelona, Spain

^d Microbiology Department, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Barcelona, Spain

Corresponding author.

E-mail address: joaquin.burgos@vallhebron.cat (J. Burgos).